These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 8529281)

  • 21. [Two cases of recurrent breast cancer successfully treated with paclitaxel weekly therapy].
    Tagaya N; Nakagawa A; Okada T; Hamada K; Mikami H; Ito S; Kubota K
    Gan To Kagaku Ryoho; 2003 Oct; 30(10):1479-83. PubMed ID: 14584281
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Head and neck cancer].
    Inuyama Y; Fukuda S; Satoh N
    Gan To Kagaku Ryoho; 1997 Oct; 24(13):1902-9. PubMed ID: 9350234
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Schedule-dependent synergism and antagonism between pemetrexed and paclitaxel in human carcinoma cell lines in vitro.
    Kano Y; Akutsu M; Tsunoda S; Izumi T; Mori K; Fujii H; Yazawa Y; Mano H; Furukawa Y
    Cancer Chemother Pharmacol; 2004 Dec; 54(6):505-13. PubMed ID: 15340759
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Selective tumor sensitization to taxanes with the mAb-drug conjugate cBR96-doxorubicin.
    Wahl AF; Donaldson KL; Mixan BJ; Trail PA; Siegall CB
    Int J Cancer; 2001 Aug; 93(4):590-600. PubMed ID: 11477565
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Paclitaxel-containing combination chemotherapy for metastatic breast cancer.
    Hortobagyi GN; Ibrahim N
    Semin Oncol; 1996 Feb; 23(1 Suppl 1):53-7. PubMed ID: 8629039
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of gamma-linolenic acid and oleic acid on paclitaxel cytotoxicity in human breast cancer cells.
    Menéndez JA; del Mar Barbacid M; Montero S; Sevilla E; Escrich E; Solanas M; Cortés-Funes H; Colomer R
    Eur J Cancer; 2001 Feb; 37(3):402-13. PubMed ID: 11239764
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Clinical efficacy of low-dose weekly docetaxel combined with oral 5'-deoxy-5-fluorouridine (5'-DFUR) in advanced or metastatic breast cancer: a pilot trial].
    Harada Y; Ohuchi N; Ohnuki K; Amano G; Yoshida R; Furuta A; Ikegaki H; Kijima G; Satomi S
    Gan To Kagaku Ryoho; 2000 Apr; 27(4):579-84. PubMed ID: 10791000
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase.
    Sirotnak FM; Zakowski MF; Miller VA; Scher HI; Kris MG
    Clin Cancer Res; 2000 Dec; 6(12):4885-92. PubMed ID: 11156248
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of paclitaxel and docetaxel (Taxotere) in gynecologic and breast cancer cell lines with the ATP-cell viability assay.
    Untch M; Untch A; Sevin BU; Angioli R; Perras JP; Koechli O; Averette HE
    Anticancer Drugs; 1994 Feb; 5(1):24-30. PubMed ID: 7910494
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Risks and benefits of taxanes in breast and ovarian cancer.
    Michaud LB; Valero V; Hortobagyi G
    Drug Saf; 2000 Nov; 23(5):401-28. PubMed ID: 11085347
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Combination treatment with fulvestrant and various cytotoxic agents (doxorubicin, paclitaxel, docetaxel, vinorelbine, and 5-fluorouracil) has a synergistic effect in estrogen receptor-positive breast cancer.
    Ikeda H; Taira N; Nogami T; Shien K; Okada M; Shien T; Doihara H; Miyoshi S
    Cancer Sci; 2011 Nov; 102(11):2038-42. PubMed ID: 21801281
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Combinations of paclitaxel and vinblastine and their effects on tubulin polymerization and cellular cytotoxicity: characterization of a synergistic schedule.
    Giannakakou P; Villalba L; Li H; Poruchynsky M; Fojo T
    Int J Cancer; 1998 Jan; 75(1):57-63. PubMed ID: 9426691
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Exogenous supplementation with omega-3 polyunsaturated fatty acid docosahexaenoic acid (DHA; 22:6n-3) synergistically enhances taxane cytotoxicity and downregulates Her-2/neu (c-erbB-2) oncogene expression in human breast cancer cells.
    Menendez JA; Lupu R; Colomer R
    Eur J Cancer Prev; 2005 Jun; 14(3):263-70. PubMed ID: 15901996
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Combination docetaxel/cyclophosphamide in patients with advanced solid tumors.
    Valero V
    Oncology (Williston Park); 1997 Aug; 11(8 Suppl 8):34-6. PubMed ID: 9364540
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The scientific rationale for developing taxoids.
    Aapro M
    Anticancer Drugs; 1996 Aug; 7 Suppl 2():33-6. PubMed ID: 8862709
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Enhancement of the efficacy of weekly low-dose taxotere by the long acting anti-prolactinemic drug cabergoline in pretreated metastatic breast cancer.
    Frontini L; Lissoni P; Vaghi M; Perego MS; Pescia S; Ardizzoia A; Gardani G
    Anticancer Res; 2004; 24(6):4223-6. PubMed ID: 15736476
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Emerging role of taxanes in adjuvant and neoadjuvant therapy for breast cancer: the potential and the questions.
    Goble S; Bear HD
    Surg Clin North Am; 2003 Aug; 83(4):943-71. PubMed ID: 12875604
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The role of taxanes in the treatment of breast cancer.
    Capri G; Tarenzi E; Fulfaro F; Gianni L
    Semin Oncol; 1996 Feb; 23(1 Suppl 2):68-75. PubMed ID: 8614849
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Schedule dependency of antitumor activity in combination therapy with capecitabine/5'-deoxy-5-fluorouridine and docetaxel in breast cancer models.
    Fujimoto-Ouchi K; Tanaka Y; Tominaga T
    Clin Cancer Res; 2001 Apr; 7(4):1079-86. PubMed ID: 11309360
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Docetaxel: an update of its use in advanced breast cancer.
    Figgitt DP; Wiseman LR
    Drugs; 2000 Mar; 59(3):621-51. PubMed ID: 10776837
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.